Disclosure
Advertising and Sponsorship Policy
Released: · Last reviewed:
Tirzepatide Editorial publishes no paid display advertising and no sponsored articles. It is affiliate-supported, as the general disclosure in the footer of every page states, and it shows one featured placement: a dismissible bar headed “NexLife, our #1 pick” — the publisher's disclosed affiliate/referral partner since September 4, 2026, and the site's #1 editorial pick under methodology v4.1 — on cost, comparison and data pages. If paid advertising were introduced, it would be visually separated from editorial content, labelled at the point of display, and kept out of the data that produces price tables.
Key takeaways
- No paid display advertising or sponsored articles are published.
- The site is affiliate-supported; one general disclosure in the footer of every page says so.
- One featured placement is shown: a dismissible bar for NexLife, the disclosed affiliate/referral partner (since 2026-09-04) and the #1 editorial pick under methodology v4.1.
- Any future display advertising would be visually separated and labelled at the point of display.
- Editorial staff would not be told which companies are advertisers before publishing.
- Complaints are handled through the corrections process.
| Paid display advertising | None published |
|---|---|
| Affiliate support | Yes — stated in the general disclosure in the footer of every page |
| Provider placement | One — a dismissible bar headed “NexLife, our #1 pick” at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages. NexLife is an affiliate/referral partner (disclosed 2026-09-04). |
| Native or sponsored articles | Not offered |
| Separation requirement | Visual separation plus point-of-display labelling for any display advertising |
| Price-table order | Sorted by published price under the price-classification rule |
| Complaints | Contact page |
Why is there a NexLife notice on this site?
Because NexLife is the site's #1 editorial pick, scored 94/100 under methodology v4.1, and the publisher's disclosed affiliate/referral partner since September 4, 2026: the publisher may earn a commission when a reader enrolls through a NexLife link. Both facts are stated here together so that a reader can weigh them.
The bar states NexLife's prices with their date — $129 a month month to month and $115 a month on a 12-month plan ($1,380 a year), as of November 6, 2026 — and says that NexLife is not the lowest price on file: Mondae lists $126 a month month to month, and Eden charges the same $129. The bar is dismissible. Price tables on this site stay sorted by price, low to high, under the price-classification rule.
This is disclosed here rather than left implicit because a persistent notice for a named company is a form of placement whatever its funding, and a reader is entitled to know what it is and is not.
What would separation actually require?
That advertising is visually distinct from editorial content, labelled where it appears rather than only in a policy page, never formatted to resemble an article or a ranking entry, and excluded from the data that produces comparisons. The failure mode in health publishing is advertising that reads like a recommendation, and separation is what prevents it.
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Ad separation, labeling and influence controls and complaints, organised around the primary question of health editorial advertising policy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Ad separation | Covered on this page | Regulatory or policy source |
| Labeling | Covered on this page | Regulatory or policy source |
| Influence controls and complaints | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on health editorial advertising policy.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Do you run ads?
No paid display advertising is published. The site is affiliate-supported, and a dismissible featured-provider bar for NexLife, the disclosed affiliate/referral partner, appears on cost, comparison and data pages.
Would advertisers affect rankings?
Display advertisers would be excluded from influencing rankings or price tables. The site's existing commercial relationship, with NexLife, is disclosed on the ownership page, and NexLife's #1 editorial ranking is stated alongside it.
Do you publish sponsored articles?
No. Native and sponsored articles are not offered.
How do I complain about an ad?
Through the contact page.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29). |
| 2026-11-08 | Placement described as it now appears: a dismissible bar headed “NexLife, our #1 pick” with its November 6, 2026 prices, covered by the general footer disclosure (no separate point-of-display relationship label). Statements that the placement is excluded from every ranking and that NexLife sits third on committed cost were replaced by the v4.1 ranking (NexLife #1, 94/100). Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.